MARKETVUE® REPORT: Over 80% of U.S. gastroenterologists have prescribed Dupixent for Eosinophilic Esophagitis since its 2022 approvalDanielle Drayton2023-02-23T18:36:00+00:00February 23rd, 2023|Read More
5 Solutions to Overcome Challenges Conducting Rare Disease EpidemiologyNina Finkhouse2021-11-18T16:56:48+00:00November 18th, 2021|Read More
3 Key Insights for Rare Disease Drug Developers: GSD Type 1aNina Finkhouse2021-09-23T18:07:27+00:00September 23rd, 2021|Read More
Hematologists Report A Strong Willingness To Prescribe Novartis’ Adakveo And Global Blood Therapeutics’ Oxbryta But Are Holding Back Due To COVID-19, Treatment Costs, And Patients Being Well-Managed On Current TherapyDanielle Drayton2020-10-05T13:14:26+00:00September 30th, 2020|Read More
MARKETVUE® REPORT: Over 80% of U.S. gastroenterologists have prescribed Dupixent for Eosinophilic Esophagitis since its 2022 approvalDanielle Drayton2023-02-23T18:36:00+00:00February 23rd, 2023|Read More
5 Solutions to Overcome Challenges Conducting Rare Disease EpidemiologyNina Finkhouse2021-11-18T16:56:48+00:00November 18th, 2021|Read More
3 Key Insights for Rare Disease Drug Developers: GSD Type 1aNina Finkhouse2021-09-23T18:07:27+00:00September 23rd, 2021|Read More
Hematologists Report A Strong Willingness To Prescribe Novartis’ Adakveo And Global Blood Therapeutics’ Oxbryta But Are Holding Back Due To COVID-19, Treatment Costs, And Patients Being Well-Managed On Current TherapyDanielle Drayton2020-10-05T13:14:26+00:00September 30th, 2020|Read More
